Product: Podoplanin Antibody
Catalog: DF12456
Description: Rabbit polyclonal antibody to Podoplanin
Application: WB IHC
Cited expt.:
Reactivity: Human, Mouse
Prediction: Dog
Mol.Wt.: 43 kDa; 17kD(Calculated).
Uniprot: Q86YL7
RRID: AB_2845261

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Prediction:
Dog(83%)
Clonality:
Polyclonal
Specificity:
Podoplanin Antibody detects endogenous levels of total Podoplanin.
RRID:
AB_2845261
Cite Format: Affinity Biosciences Cat# DF12456, RRID:AB_2845261.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Aggrus; Glycoprotein 36 KD; Glycoprotein 36; gp 36; GP 38; GP 40; gp36; GP38; GP40; HT1A 1; HT1A1; hT1alpha 1; hT1alpha 2; hT1alpha1; hT1alpha2; Lung type I cell membrane associated glycoprotein; Lung type I cell membrane associated glycoprotein isoform a; Lung type I cell membrane associated glycoprotein T1A 2; OTS 8; OTS8; OTTHUMP00000009640; OTTHUMP00000044504; PA2.26; PA2.26 antigen; Pdpn; PDPN_HUMAN; Podoplanin; PSEC0003; PSEC0025; T1 alpha; T1 ALPHA GENE; T1-alpha; T1A 2; T1A; TI1A; TIA 2; TIA2;

Immunogens

Immunogen:

A synthesized peptide derived from human Podoplanin, corresponding to a region within N-terminal amino acids.

Uniprot:
Gene(ID):
Expression:
Q86YL7 PDPN_HUMAN:

Highly expressed in placenta, lung, skeletal muscle and brain. Weakly expressed in brain, kidney and liver. In placenta, expressed on the apical plasma membrane of endothelium. In lung, expressed in alveolar epithelium. Up-regulated in colorectal tumors and expressed in 25% of early oral squamous cell carcinomas.

Sequence:
MWKVSALLFVLGSASLWVLAEGASTGQPEDDTETTGLEGGVAMPGAEDDVVTPGTSEDRYKSGLTTLVATSVNSVTGIRIEDLPTSESTVHAQEQSPSATASNVATSHSTEKVDGDTQTTVEKDGLSTVTLVGIIVGVLLAIGFIGAIIVVVMRKMSGRYSP

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Dog
83
Pig
0
Horse
0
Bovine
0
Sheep
0
Xenopus
0
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Mediates effects on cell migration and adhesion through its different partners. During development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation. Interaction with CD9, on the contrary, attenuates platelet aggregation induced by PDPN. Through MSN or EZR interaction promotes epithelial-mesenchymal transition (EMT) leading to ERZ phosphorylation and triggering RHOA activation leading to cell migration increase and invasiveness. Interaction with CD44 promotes directional cell migration in epithelial and tumor cells. In lymph nodes (LNs), controls fibroblastic reticular cells (FRCs) adhesion to the extracellular matrix (ECM) and contraction of the actomyosin by maintaining ERM proteins (EZR; MSN and RDX) and MYL9 activation through association with unknown transmembrane proteins. Engagement of CLEC1B by PDPN promotes FRCs relaxation by blocking lateral membrane interactions leading to reduction of ERM proteins (EZR; MSN and RDX) and MYL9 activation (By similarity). Through binding with LGALS8 may participate to connection of the lymphatic endothelium to the surrounding extracellular matrix. In keratinocytes, induces changes in cell morphology showing an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility and decreased cell adhesion. Controls invadopodia stability and maturation leading to efficient degradation of the extracellular matrix (ECM) in tumor cells through modulation of RHOC activity in order to activate ROCK1/ROCK2 and LIMK1/LIMK2 and inactivation of CFL1. Required for normal lung cell proliferation and alveolus formation at birth (By similarity). Does not function as a water channel or as a regulator of aquaporin-type water channels. Does not have any effect on folic acid or amino acid transport (By similarity).

PTMs:

Extensively O-glycosylated. Contains sialic acid residues. O-glycosylation is necessary for platelet aggregation activity. Disialylated at Thr-52; sialic acid is critical for platelet-aggregating activity and for CLEC1B interaction.

The N-terminus is blocked.

Cleaved by a metalloprotease within its extracellular (EC) domain, generating a membrane-bound C-terminal fragment (PCTF33) and an extracellular fragment. The resulting membrane-bound C-terminal fragment (PCTF33) is further processed between Val-150 and Val-151 by PSEN1/gamma-secretase generating the intracellular domain of podoplanin (PICD).

Subcellular Location:

Membrane>Single-pass type I membrane protein. Cell projection>Lamellipodium membrane>Single-pass type I membrane protein. Cell projection>Filopodium membrane>Single-pass type I membrane protein. Cell projection>Microvillus membrane>Single-pass type I membrane protein. Cell projection>Ruffle membrane>Single-pass type I membrane protein. Membrane raft. Apical cell membrane. Basolateral cell membrane. Cell projection>Invadopodium.
Note: Localized to actin-rich microvilli and plasma membrane projections such as filopodia, lamellipodia and ruffles (By similarity). Association to the lipid rafts is required for PDPN-induced epithelial to mesenchymal transition (EMT) (PubMed:21376833). Colocalizes with CD9 in tetraspanin microdomains (PubMed:18541721). Localized at invadopodium adhesion rings in tumor cell. Association to the lipid rafts is essential for PDPN recruitment to invadopodia and ECM degradation (PubMed:25486435).

Cytoplasm>Cytosol.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Highly expressed in placenta, lung, skeletal muscle and brain. Weakly expressed in brain, kidney and liver. In placenta, expressed on the apical plasma membrane of endothelium. In lung, expressed in alveolar epithelium. Up-regulated in colorectal tumors and expressed in 25% of early oral squamous cell carcinomas.

Family&Domains:

The cytoplasmic domain controls FRC elongation but is dispensable for contraction (By similarity). The cytoplasmic domain is essential for recruitment to invadopodia and ECM degradation (PubMed:25486435).

Belongs to the podoplanin family.

References

1). TRβ activation confers AT2-to-AT1 cell differentiation and anti-fibrosis during lung repair via KLF2 and CEBPA. Nature communications, 2024 (PubMed: 39375377) [IF=16.6]

Application: IF/ICC    Species: Mouse    Sample: AT1 cells

Fig. 2: TRα facilitates cell proliferation, while TRβ promotes AT2 cells differentiation into AT1 cells. a The heatmap of indicated gene expression in the HLCA and MCA data. b EdU assay in MRC5 after THRA and THRB overexpression for 24 h with 10 nM T3 for another 24 h (n = 3). Scale bar, 100 μm. c EdU assay in MRC5 with or without 10 nM T3 or GC-1 treatment (n = 5). Scale bar, 100 μm. d Workflow of the intervention with hypothyroidism and GC-1 in the differentiation phase of the PNX model. e qPCR analysis of AT1 cell markers (Ager, Hopx, and Pdpn) in lung homogenates (n = 3, 3, 4, 4). f, g Representative IF images and quantification show AT1 cells differentiated from AT2 cells (indicated by arrows) (n = 3). Scale bars, 50 μm. h–k Experimental workflow for 3D-organoid culture and GC-1 treatment. Cont., continued GC-1 from day 0. Late, GC-1 for the last 4 days (h). Representative images of colonies in wells, H&E staining, and IF. Scale bars, top 2 mm, middle and bottom, 50 μm (i). Colony average area and colony-forming efficiency of 3D-organoids (n = 4) (j). Quantification of AT1 cell markers by qPCR (n = 4) (k). The value of n indicates biologically independent samples. Similar results were repeated in two biologically independent experiments. Data are presented as mean ± SEM. Statistical significance among groups was determined using one-way ANOVA.

2). Multiomic identification of senescent stem cell populations critical for osteoarthritis progression and therapy in subchondral bones. Science advances, 2025 (PubMed: 40680126) [IF=11.7]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.